deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT02125253

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

A Blinded, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg (Amneal Pharmaceuticals LLC) With NASONEX® Nasal Spray (Schering Corporation) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Sponsor: Amneal Pharmaceuticals, LLC

Conditions Seasonal Allergic Rhinitis
Interventions Mometasone Furoate Nasal Spray, 50 mcg Nasonex Nasal Spray, 50 mcg Placebo Nasal Spray
Updated 7 times since 2017 Last updated: Oct 5, 2015 Started: Jan 31, 2014 Primary completion: Mar 31, 2014 Completion: Jun 30, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02125253, this PHASE3 trial focuses on Seasonal Allergic Rhinitis and remains completed. Sponsored by Amneal Pharmaceuticals, LLC, it has been updated 7 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotCompleted~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Amneal Pharmaceuticals, LLC
  • Novum Pharmaceutical Research Services
Data source: Amneal Pharmaceuticals, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations